H.E. Akalin
Pfizer
3 Papers
16 Citations
H.E. Akalin is an academic researcher from Pfizer. The author has contributed to research in topics: Ampicillin & Antibacterial agent. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
The place of antibiotic therapy in the management of chronic acute exacerbations of chronic bronchitis
TL;DR: Antibiotic therapy should be initiated based on patient history and severity of the exacerbation, with an increase from baseline in one or more or the following; dyspnoea, cough and/or sputum volume, purulence or viscosity.
10
The role of β-lactam/β-lactamase inhibitors in the management of mixed infections
TL;DR: Microbiological studies show that the in vitro antimicrobial activity of sulbactam–ampicillin encompasses not only Gram-positive and Gram-negative aerobes, but also anaerobes that suggest its suitability as monotherapy for the empiric management of polymicrobial infections.
8
Clinical implications of aminopenicillins with β-lactamase inhibitors
TL;DR: Clinical studies have revealed that aminopenicillin/beta-lactamase inhibitors may provide therapy or prophylaxis which is more cost-effective than with comparative antimicrobial agents.
1